Invivyd Q3 net loss beats estimates on higher PEMGARDA sales among healthcare providers

Invivyd

06/11/2025 12:27

Overview

Invivyd Q3 2025 revenue grows 41% yr/yr to $13.1 mln

Net loss for Q3 2025 beats analyst estimates

Adjusted loss per share for Q3 2025 beats consensus

Company receives FDA clearance for VYD2311 clinical program

Outlook

Invivyd expects to begin pivotal trials for VYD2311 by year-end 2025

Top-line data for VYD2311 trials anticipated mid-2026

Company plans pipeline expansion beyond COVID to include RSV and measles

Result Drivers

PEMGARDA SALES - Growth in PEMGARDA sales among healthcare providers treating immunocompromised patients contributed to revenue increase

FDA CLEARANCE - FDA clearance for VYD2311 clinical program positions Invivyd for future growth in COVID-19 prevention

CASH POSITION - Cash reserves strengthened by public offering and ATM facility usage, supporting future investments

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$13.13 mln
Q3 EPS
Beat
-$0.06
-$0.08 (3 Analysts)
Q3 Net Income
Beat
-$10.47 mln
-$12.44 mln (2 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Invivyd Inc is $10.00, about 84.8% above its November 5 closing price of $1.52

Press Release: ID:nGNX3zFg4p

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)